, and AF-CHF (Atrial Fibrillation and Congestive Heart Failure) (7) . Simply stated, these 9 trials showed no important advantage of either strategy with respect to major clinical outcomes, such as death, stroke, and worsening heart failure. Attempting to restore and maintain sinus rhythm is better for symptom control in highly symptomatic patients, and controlling the heart rate is less expensive.
AS THESE RESULTS ARE BASED ON CLINICAL PRACTICE PATTERNS AND KNOWLEDGE

THAT IS 2 DECADES OLD, COULD THE SITUATION HAVE CHANGED?
On a theoretical basis, several benefits are expected to accrue from restoring atrioventricular synchrony, which also controls heart rate and bestows regularity.
The lingering hypothesis that restoration and maintenance of sinus rhythm is superior to simply controlling the heart rate has been bolstered by a number From the Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada. Dr. Wyse has reported that he has no relationships relevant to the contents of this paper to disclose. Of course that level of evidence cannot overturn the results of well-done randomized, controlled trials because of inherent flaws in the study design, mostly because all the potentially important covariates are not available and perhaps not even known (10) . Such studies also often have a limited scope because retrospective administrative databases were not designed to study AF and included only selected samples of patients (e.g., those older than 65 years of age or those with a hospital admission for AF).
Finally, there is rarely adjustment for important timedependent covariates (those only evident after study entry). The pitfall is that the "new data" cachet can be seductive, leading some to neglect results from earlier randomized, controlled clinical trials considered to be "old" and "passé."
ORBIT-AF is a comparative cohort study of similar design, but with the major advantage that it is a prospectively designed database specifically inten- focused on patients younger than 65 years of age without structural heart disease found that only 7% of such patients treated with antiarrhythmic agents were treated with dronedarone (13) . Thus, although we do not know for sure, it can be deduced that use of dronedarone was low In ORBIT-AF (median age w75 years). Therefore, it seems unlikely that dronedarone had much impact on the outcomes.
COULD NONPHARMACOLOGICAL THERAPIES HAVE MADE AN IMPACT NOT SEEN IN THE EARLIER RANDOMIZED, CONTROLLED TRIALS?
Since the major rate versus rhythm trials were done had a surgical maze procedure, and 1 had a catheterbased maze procedure (5). The current "big question" is whether these nonpharmacological therapies may have shifted the "no-difference" paradigm.
In this ORBIT-AF report, we are not specifically told how many were treated initially with catheter-or surgery-based ablation procedures, but we are told that 13.1% had AF ablation procedures during the course of the study (4). We can see from Table 3 that Hospital Drive NW, Calgary AB T2N 4Z6, Canada.
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